BTIG analyst Ryan Zimmerman has maintained their neutral stance on PRCT stock, giving a Hold rating on October 24.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Zimmerman has given his Hold rating due to a combination of factors impacting PROCEPT BioRobotics. The company’s recent quarterly results showed revenue exceeding expectations, driven by strong performance in US Systems and international sales. However, there were concerns about the softness in handpiece utilization growth and a decline in average selling prices for their HYDROS systems. The new CEO has acknowledged the need for improved utilization, which remains a focal point for the company.
Despite efforts to reassure investors about growth prospects, management’s comments on longer sales cycles and inventory adjustments have contributed to a cautious outlook. Preliminary revenue guidance for the upcoming fiscal year suggests that consensus estimates may need to be adjusted downward, and the company must demonstrate better operational execution to bolster confidence. While valuation has decreased, concerns about slowing utilization and high expectations persist, leading to the Hold rating.
In another report released on October 24, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $35.00 price target.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRCT in relation to earlier this year.